Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von NightTrain 

Bristol-Myers Squibb diskutieren

Bristol-Myers Squibb

WKN: 850501 / Symbol: BMY / Name: Bristol-Myers / Aktie / Pharmazeutika / Large Cap /

48,04 €
0,08 %

Bristol-Myers Squibb (NYSE: BMY) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Ratings data for BMY provided by MarketBeat

Einschätzung Buy
Rendite (%) 15,23 %
Kursziel 59,59
Veränderung
Endet am 23.04.26

Bristol-Myers Squibb (NYSE: BMY) had its price target lowered by analysts at Jefferies Financial Group Inc. from $70.00 to $68.00. They now have a "buy" rating on the stock.
Ratings data for BMY provided by MarketBeat

Einschätzung Sell
Rendite (%) 16,79 %
Kursziel 28,95
Veränderung
Endet am 10.07.26

Bristol Myers Squibb Company (NYSE: BMY) had its price target lowered by analysts at Morgan Stanley from $36.00 to $34.00. They now have an "underweight" rating on the stock.
Ratings data for BMY provided by MarketBeat

Bristol Myers Squibb (NYSE:BMY) had its "underweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for BMY provided by MarketBeat

Einschätzung Buy
Rendite (%) 4,45 %
Kursziel 51,96
Veränderung
Endet am 15.12.26

Bristol Myers Squibb (NYSE:BMY) was upgraded by analysts at Bank of America Corporation from a "neutral" rating to a "buy" rating. They now have a $61.00 price target on the stock, up previously from $52.00.
Ratings data for BMY provided by MarketBeat

Bristol Myers Squibb (NYSE:BMY) had its "buy" rating reaffirmed by analysts at Guggenheim.
Ratings data for BMY provided by MarketBeat

Einschätzung Buy
Rendite (%) 1,13 %
Kursziel 55,55
Veränderung
Endet am 07.01.27

Bristol Myers Squibb (NYSE:BMY) was upgraded by analysts at UBS Group AG from a "neutral" rating to a "buy" rating. They now have a $65.00 price target on the stock.
Ratings data for BMY provided by MarketBeat

Einschätzung Buy
Rendite (%) -0,96 %
Kursziel 51,46
Veränderung
Endet am 13.01.27

Bristol Myers Squibb (NYSE:BMY) had its price target raised by analysts at Leerink Partners from $54.00 to $60.00. They now have an "outperform" rating on the stock.
Ratings data for BMY provided by MarketBeat